Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 6/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028306 | 0.94 | OPRM1 (0.46) | RENOPRM1NTMT1NTSR2 | |
| SCHEMBL30800861 | 0.89 | DPP4 (0.43) | RENOPRM1 | |
| SCHEMBL31399255 | 0.87 | REN (0.44) | RENOPRM1NTMT1NTSR2 | |
| SCHEMBL29962469 | 0.86 | REN (0.44) | RENOPRM1NTMT1ACENTSR2 | |
| SCHEMBL29669249 | 0.86 | REN (0.45) | RENOPRM1NTSR2 | |
| SCHEMBL29350551 | 0.85 | GRB2 (0.56) | NTSR2 | |
| SCHEMBL30937369 | 0.84 | REN (0.43) | RENOPRM1ACENTSR2 | |
| SCHEMBL29658176 | 0.84 | GRB2 (0.44) | RENOPRM1NTSR2 | |
| SCHEMBL28758609 | 0.84 | REN (0.44) | KDM1ARENOPRM1 | |
| SCHEMBL29801925 | 0.82 | REN (0.45) | RENACENTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | KDM1A 4859/4885REN 281/4885TACR1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.